Philips Launches Occlusion Balloon Capable of Reducing Blood Loss by 90%
Royal Philips announces the launch of the Bridge Plus Occlusion Balloon, a next-generation balloon designed for electrophysiology teams. This device quickly controls bleeding during superior vena cava tears in transvenous lead extraction procedures.
The Bridge Plus is engineered to ensure temporary vessel occlusion, reduce bleeding, and maintain hemostasis during emergencies. According to the press release, the balloon deploys in less than two minutes, reduces blood loss by up to 90%, and maintains acceptable hemostasis for at least 30 minutes. This technology is based on a platform proven in over 50,000 procedures. The device is equipped with radiopaque markers for precise positioning and adapts to a wide range of patient anatomies.
Availability and Upcoming Presentation
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
The Bridge Plus Occlusion Balloon is now available in the United States. International availability is expected later in 2026, subject to national regulatory approvals. The device will be featured at the Heart Rhythm Society congress 2026, which will be held from April 24 to 26 in Chicago. This initiative expands Philips' portfolio of lead management solutions dedicated to safe and effective extraction procedures.
SectorSanté · Technologie · Equipements médicaux›Équipements Médicaux
Context
Period
Period: 1T2026
Key reported figures
Revenue: 3.9MD€
Free cash flow: 28M€
Guidance from the release
Nous avons délivré un bon départ en 2026.
Bonne performance au T1, croissance des ventes et des marges.
Risks mentioned
Impact des tarifs et inflation des coûts sur les marges.
Environnement macroéconomique incertain impactant les performances.
Opportunities identified
Croissance des ventes comparables de 4% dans tous les segments.
Augmentation du carnet de commandes grâce à des innovations.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
